4SC AG has licensed, on an exclusive basis, its investigational pan-histone deacetylase (HDAC) inhibitor for oncology, resminostat, to Yakult Honsha Co Ltd for development and commercialisation in Japan.
An advisory panel of the US Food and Drug Administration has recommended that Afinitor (everolimus) be approved for patients with advanced neuroendocrine tumours of pancreatic origin, according to Novartis, the drug’s developer.
Medivir AB has announced an offer to acquire the Nordic speciality pharmaceutical company, BioPhausia AB, in a cash and share offer that values BioPhausia at about SEK 565 million (€62 million). The offer was announced on 11 April 2011.
Cellectis SA of France has arranged financing for an ambitious project to produce induced pluripotent stem cells (iPS) on an industrial scale so that they can be used for a range of commercial applications, including the production of red blood cells.
Venture-capital backed Heptares Therapeutics Ltd of the UK has received £1.7 million upfront in a collaboration deal with the Takeda Pharmaceutical Company to discover drugs for central nervous system disorders focused on a GPCR target.
Intercell AG, and its partner Merck & Co, have announced that they are temporarily suspending enrollment in a Phase 2/3 trial of a vaccine for the prevention of Staphylococcus aureus infection on the advice of the data monitoring committee.
Novartis has announced that it is discontinuing a Phase 3 trial of the drug, Tasigna (nilotinib), for the first-line treatment of gastrointestinal stromal tumours (GIST) on the advice of an independent data monitoring committee.
Two UK speciality pharmaceutical companies, Sinclair Pharma Plc and IS Pharma Plc, have reached agreement on the terms of an all-share merger that will create a new UK-based speciality pharma business with product distribution throughout Europe.
The nonprofit drug discovery affiliate of the Cystic Fibrosis Foundation is expanding a collaboration with Vertex Pharmaceuticals Inc to develop new medicines called ‘correctors’ that aim to treat the underlying cause of cystic fibrosis.
Privately-held Astex Therapeutics Ltd of the UK has agreed to be acquired by the California-based oncology drug developer SuperGen Inc to create a new publicly-listed entity with a combined clinical pipeline of eight products.